Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021.  Martinez A, Khan T, Dylla DE, Marcinak J, Collins M, Saget B, Conway B.  Harm Reduct J. 2023 Oct 1;20(1):142. doi: 10.1186/s12...

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.  Stemkens R, Jager Vd, Dawson R, Diacon AH, Narunsky K, Padayachee SD, Boeree MJ, van Beek SW, Colbers A, Coenen MJH, Svensson EM, Fuhr U, Phillips PP...

Non-fatal overdose risk associated with prescribing opioid agonists concurrently with other medication: Cohort study conducted using linked primary care, secondary care and mortality records. Domzaridou, E, Carr, MJ, Millar, T, Webb...

Psychopharmaka-Interaktionen in der Suchttherapie ÖGABS 2023 Mag. pharm. Sonja Habib-MayeraHPh, Klinische Pharmazie, KH-Apotheke amNeuromedCampus Kepler Universitätsklinikum, Linz Präsentation https://oegabs.at/userfiles/files/substi...

Variation in adverse drug events of opioids in the United States.  Liu EY, McCall KL, Piper BJ.  Front Pharmacol. 2023 Mar 24;14:1163976. doi: 10.3389/fphar.2023.1163976. PMID: 37033633; PMCID: PMC10079914. https://www.ncbi.nlm.nih.go...

Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study.  Elkrief L, Bastien G, McAnulty C, Bakouni H, Hébert FO, Socias ME, Le Foll B, Lim R, Ledjiar O, Marsan S, Brissette S, Jut...